1. |
Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet, 2022, 400(10354): 769-786.
|
2. |
Zhao MY, Wang LQ, Wang MZ, et al. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther, 2022, 7(1): 206.
|
3. |
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Eng J Med, 2014, 370(22): 2071-2082.
|
4. |
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011, 377(9779): 1760-1769.
|
5. |
万一千, 柯衡明, 陈功, 等. 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用. 中国: ZL 201010501383.2 (中国专利), 2012-12-12.
|
6. |
赵子建, 穆云萍, 李芳红, 等. 一种5型磷酸二酯酶抑制剂的钾盐晶型B及其制备方法和应用. 中国: ZL 201910505948.5 (中国专利), 2022-03-01.
|
7. |
朱惠丹, 柯嘉琪, 王家璐, 等. 新型磷酸二酯酶5抑制剂CPD1对肺动脉高压大鼠血管收缩的影响. 中国药理学通报, 2021, 37(3): 328-337.
|
8. |
刘晓晴, 杨建钦, 王栩林, 等. 新型磷酸二酯酶5抑制剂CPD1对异丙肾上腺素诱导心肌肥厚大鼠心脏的保护作用. 中国药理学通报, 2022, 38(9): 1280-1287.
|
9. |
封文斌, 杨建钦, 陈心慧, 等. 新型磷酸二酯酶5抑制剂CPD1对四氯化碳诱导的肝纤维化小鼠治疗作用. 中国药理学通报, 2023, 39(3): 470-476.
|
10. |
刘傲璐, 李壮, 卢美芝, 等. 新型磷酸二酯酶5抑制剂CPD1对单侧肾缺血再灌注损伤后肾间质纤维化的影响. 生理学报, 2023, 75(1): 1-9.
|
11. |
刘傲璐, 任倩, 封文斌, 等. 新型磷酸二酯酶5抑制剂CPD1对单侧输尿管梗阻引起的肾间质纤维化小鼠治疗作用. 中国药理学通报, 2023, 39(1): 147-152.
|
12. |
B Moore B, Lawson WE, Oury TD, et al. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol, 2013, 49(2): 167-179.
|
13. |
庄永杰, 陈继巧. 一种大鼠单侧肺肺纤维化模型的建立. 中国: CN105148254A (中国专利), 2015-12-16.
|
14. |
Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med, 2022, 28(11): 2398-2405.
|
15. |
Lamb YN. Nintedanib: a review in fibrotic interstitial lung diseases. Drugs, 2021, 81(5): 575-586.
|
16. |
Gulati S, Luckhardt TR. Updated evaluation of the safety, efficacy and tolerability of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Drug Healthc Patient Saf, 2020, 12: 85-94.
|
17. |
林荣梅, 柴燕玲. 进展性肺纤维化诊治进展. 中国呼吸与危重监护杂志, 2023, 22(1): 66-70.
|
18. |
Rockey DC, Bell PD, Hill JA. Fibrosis--a common pathway to organ injury and failure. N Engl J Med, 2015, 372(12): 1138-1149.
|
19. |
Jenkins RG, Moore BB, Chambers RC, et al. An Official American Thoracic Society Workshop Report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol, 2017, 56(5): 667-679.
|
20. |
欧阳小荔, 彭红. 特发性肺纤维化预后的影响因素. 中国呼吸与危重监护杂志, 2021, 20(11): 824-830.
|